Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 36-50 , January 2006

Future Direction of Renal Positron Emission Tomography

  • Zsolt Szabo, MD, PhD

      Affiliations

    • Division of Nuclear Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
    • Corresponding Author InformationAddress reprint requests to Zsolt Szabo, MD, PhD, Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, The Johns Hopkins Medical Institutions, 601 N. Caroline Street, Baltimore, MD 21287.
    • ,
  • Jinsong Xia, MD, PhD

      Affiliations

    • Division of Nuclear Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
    • ,
  • William B. Mathews, PhD

      Affiliations

    • Division of Nuclear Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
    • ,
  • Phillip R. Brown, DVM

      Affiliations

    • Division of Nuclear Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
    • Department of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

References 

  1. Hewitt SM , Dear J , Star RA . Discovery of protein biomarkers for renal diseases . J Am Soc Nephrol . 2004;15:1677–1689
  2. Lorenz CH , Powers TA , Partain CL . Quantitative imaging of renal blood flow and function . Invest Radiol . 1992;27(suppl):S109–S114
  3. Romero JC , Lerman LO . Novel noninvasive techniques for studying renal function in man . Semin Nephrol . 2000;20:456–462
  4. Townsend DW . Physical principles and technology of clinical PET imaging . Ann Acad Med Singapore . 2004;33:133–145
  5. Judenhofer MS , Pichler BJ , Cherry SR . Evaluation of high performance data acquisition boards for simultaneous sampling of fast signals from PET detectors . Phys Med Biol . 2005;50:29–44
  6. Kontaxakis G , Strauss LG , Thireou T , et al.   Iterative image reconstruction for clinical PET using ordered subsets, median root prior, and a web-based interface . Mol Imaging Biol . 2002;4:219–231
  7. Gutman F , Gardin I , Delahaye N , et al.   Optimisation of the OS-EM algorithm and comparison with FBP for image reconstruction on a dual-head camera (a phantom and a clinical 18F-FDG study) . Eur J Nucl Med Mol Imaging . 2003;30:1510–1519
  8. Koepfli P , Hany TF , Wyss CA , et al.   CT attenuation correction for myocardial perfusion quantification using a PET/CT hybrid scanner . J Nucl Med . 2004;45:537–542
  9. Kaatee R , Beek FJ , de Lange EE , et al.   Renal artery stenosis (detection and quantification with spiral CT angiography versus optimized digital subtraction angiography) . Radiology . 1997;205:121–127
  10. Kim TS , Chung JW , Park JH , et al.   Renal artery evaluation (comparison of spiral CT angiography to intra-arterial DSA) . J Vasc Interv Radiol . 1998;9:553–559
  11. Carlos RC , Axelrod DA , Ellis JH , et al.   Incorporating patient-centered outcomes in the analysis of cost-effectiveness (imaging strategies for renovascular hypertension) . AJR Am J Roentgenol . 2003;181:1653–1661
  12. Alpert NM , Rabito CA , Correia DJ , et al.   Mapping of local renal blood flow with PET and H(2)(15)O . J Nucl Med . 2002;43:470–475
  13. Fine EJ , Li Y , Blaufox MD . Parenchymal mean transit time analysis of 99mTc-DTPA captopril renography . J Nucl Med . 2000;41:1627–1631
  14. Szabo Z , Vosberg H , Sondhaus CA , Feinendegen LE . Model identification and estimation of organ-function parameters using radioactive tracers and the impulse-response function . Eur J Nucl Med . 1985;11:265–274
  15. Torsello G , Szabo Z , Vosberg H . Experimental studies on renal transfer function. Effects of renal artery stenosis and occlusion . Edizioni Minerva Medica . 1985;125–127
  16. Yamashita M , Inaba T , Kawase Y , et al.   Quantitative measurement of renal function using Ga-68-EDTA . Tohoku J Exp Med . 1988;155:207–208
  17. Gjedde A . Compartmental analysis . In:  Wagner HN ,  Szabo Z ,  Buchanan WJ editor. Principles of Nuclear Medicine . Philadelphia: Saunders; 1995;p. 451–461
  18. Logan J . Graphical analysis of PET data applied to reversible and irreversible tracers . Nucl Med Biol . 2000;27:661–670
  19. Nitzsche EU , Choi Y , Killion D , et al.   Quantification and parametric imaging of renal cortical blood flow in vivo based on Patlak graphical analysis . Kidney Int . 1993;44:985–996
  20. Gjedde A , Wong DF , Wagner HN . Transient analysis of irreversible and reversible tracer binding in human brain . In:  Battistin L ,  Gerstenbrand F editor. PET and NMR (New Perspectives in Neuroimaging and in Clinical Neurochemistry) . New York: Alan R: Liss, Inc; 1985;p. 223–235
  21. Patlak CS , Blasberg RG , Fenstermacher JD . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data . J Cereb Blood Flow Metab . 1983;3:1–7
  22. Szabo Z , Kao PF , Burns HD , et al.   Investigation of angiotensin II/AT1 receptors with carbon-11-L-159, 884 (A selective AT1 antagonist) . J Nucl Med . 1998;39:1209–1213
  23. Hutchins GD . What is the best approach to quantify myocardial blood flow with pet? . J Nucl Med . 2001;42:1183–1184
  24. Mullani NA , Ekas RD , Marani S , et al.   Feasibility of measuring first pass extraction and flow with rubidium-82 in the kidneys . Am J Physiol Imaging . 1990;5:133–140
  25. Tamaki N , Rabito CA , Alpert NM , et al.   Serial analysis of renal blood flow by positron tomography with rubidium-82 . Am J Physiol . 1986;251:H1024–H1030
  26. Young H , Carnochan P , Zweit J , et al.   Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model . Eur J Nucl Med . 1994;21:336–341
  27. Shelton ME , Green MA , Mathias CJ , et al.   Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography . Circulation . 1990;82:990–997
  28. Young H , Carnochan P , Zweit J , et al.   R: Tissue blood flow estimation with copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) and PET . J Nucl Biol Med . 2002;38(suppl 1):89–91
  29. Killion D , Nitzsche E , Choi Y , et al.   Positron emission tomography (a new method for determination of renal function) . J Urol . 1993;150:1064–1068
  30. Goethals P , Volkaert A , Vandewielle C , et al.   55Co-EDTA for renal imaging using positron emission tomography (PET) (a feasibility study) . Nucl Med Biol . 2000;27:77–81
  31. Karanikas G , Becherer A , Wiesner K , et al.   ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis . Eur J Nucl Med Mol Imaging . 2002;29:312–318
  32. Clorius JH , Hupp T , Zuna I , et al.   The exercise renogram and its interpretation . J Nucl Med . 1997;38:1146–1151
  33. Imanishi M , Yano M , Okumura M , et al.   Aspirin renography in diagnosis of unilateral renovascular hypertension . Hypertens Res . 1998;21:209–213
  34. Shreve P , Chiao PC , Humes HD , et al.   Carbon-11-acetate PET imaging in renal disease . J Nucl Med . 1995;36:1595–1601
  35. Oyama N , Miller TR , Dehdashti F , et al.   11C-acetate PET imaging of prostate cancer (detection of recurrent disease at PSA relapse) . J Nucl Med . 2003;44:549–555
  36. Kotzerke J , Volkmer BG , Glatting G , et al.   Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer . Nuclearmedizin . 2003;42:25–30
  37. Seltzer MA , Jahan SA , Sparks R , et al.   Radiation dose estimates in humans for (11)C-acetate whole-body PET . J Nucl Med . 2004;45:1233–1236
  38. Nabulsi NB , Smith DE , Kilbourn MR . [(11)C]Glycylsarcosine (synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice) . Bioorg Med Chem . 2005;13:2993–3001
  39. Han HK , Amidon GL . Targeted prodrug design to optimize drug delivery . AAPS PharmSci . 2000;2:E6
  40. Terada T , Inui K . Peptide transporters (Structure, function, regulation and application for drug delivery) . Curr Drug Metab . 2004;5:85–94
  41. Nielsen CU , Brodin B . Di/tri-peptide transporters as drug delivery targets (Regulation of transport under physiological and patho-physiological conditions) . Curr Drug Targets . 2003;4:373–388
  42. Theis S , Knutter I , Hartrodt B , et al.   Synthesis and characterization of high affinity inhibitors of the H+/peptide transporter PEPT2 . J Biol Chem . 2002;277:7287–7292
  43. Padhy AK , Solanki KK , Bomanji J , et al.   Clinical evaluation of 99mTc diaminocyclohexane, a renal tubular agent with cationic transport (results in healthy human volunteers) . Nephron . 1993;65:294–298
  44. Wild D , Macke HR , Waser B , et al.   68Ga-DOTANOC (a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5) . Eur J Nucl Med Mol Imaging . 2005;32:724
  45. Prakash S , Went MJ , Blower PJ . Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use . Nucl Med Biol . 1996;23:543–549
  46. Jones-Wilson TM , Deal KA , Anderson CJ , et al.   The in vivo behavior of copper-64-labeled azamacrocyclic complexes . Nucl Med Biol . 1998;25:523–530
  47. Yoo J , Reichert DE , Kim J , et al.   A potential Dubin-Johnson syndrome imaging agent (synthesis, biodistribution, and microPET imaging) . Mol Imaging . 2005;4:18–29
  48. Paulusma CC , Kool M , Bosma PJ , et al.   A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome . Hepatology . 1997;25:1539–1542
  49. Sun X , Kim J , Martell AE , et al.   In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands . Nucl Med Biol . 2004;31:1051–1059
  50. Heilig CW , Brosius FC , Henry DN . Glucose transporters of the glomerulus and the implications for diabetic nephropathy . Kidney Int Suppl . 1997;60:S91–S99
  51. Wright EM . Renal Na(+)-glucose cotransporters . Am J Physiol Renal Physiol . 2001;280:F10–F18
  52. Bormans GM , Van Oosterwyck G , de Groot TJ , et al.   Synthesis and biologic evaluation of (11)c-methyl-d-glucoside, a tracer of the sodium-dependent glucose transporters . J Nucl Med . 2003;44:1075–1081
  53. de Groot TJ , Veyhl M , Terwinghe C , et al.   Synthesis of 18F-fluoroalkyl-beta-D-glucosides and their evaluation as tracers for sodium-dependent glucose transporters . J Nucl Med . 2003;44:1973–1981
  54. Shirota K , Kato Y , Suzuki K , Sugiyama Y . Characterization of novel kidney-specific delivery system using an alkylglucoside vector . J Pharmacol Exp Ther . 2001;299:459–467
  55. Hwang DR , Eckelman WC , Mathias CJ , et al.   Positron-labeled angiotensin-converting enzyme (ACE) inhibitor (fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography) . J Nucl Med . 1991;32:1730–1737
  56. Markham J , McCarthy TJ , Welch MJ , et al.   In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. I: Theory and error analysis . J Appl Physiol . 1995;78:1158–1168
  57. Schuster DP , McCarthy TJ , Welch MJ , et al.   In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. II: Implementation and application . J Appl Physiol . 1995;78:1169–1178
  58. Matarrese M , Salimbeni A , Turolla EA , et al.   11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat . Bioorg Med Chem . 2004;12:603–611
  59. Akcay A , Sezer S , Ozdemir FN , et al.   Association of the genetic polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction . Transplantation . 2004;78:892–898
  60. Kaschina E , Unger T . Angiotensin AT1/AT2 receptors (regulation, signalling and function) . Blood Press . 2003;12:70–88
  61. Nickenig G , Strehlow K , Roeling J , et al.   Salt induces vascular AT1 receptor overexpression in vitro and in vivo . Hypertension . 1998;31:1272–1277
  62. Strehlow K , Wassmann S , Bohm M , et al.   Angiotensin AT1 receptor over-expression in hypercholesterolaemia . Ann Med . 2000;32:386–389
  63. Sodhi CP , Kanwar YS , Sahai A . Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells . Am J Physiol Heart Circ Physiol . 2003;284:H846–H852
  64. Dumont EC , Rafrafi S , Laforest S , et al.   Involvement of central angiotensin receptors in stress adaptation . Neuroscience . 1999;93:877–884
  65. Wu Z , Maric C , Roesch D , et al.   Estrogen regulates adrenal angiotensin type 1 receptors by modulating AT1 receptor translation . Endocrinology . 2003;144:3251–3261
  66. Harrison-Bernard LM , Schulman IH , Raij L . Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity . Hypertension . 2003;42:1157–1163
  67. Nickenig G , Roling J , Strehlow K , et al.   Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms . Circulation . 1998;98:2453–2460
  68. Nickenig G , Bohm M . Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia . Eur J Med Res . 1997;2:285–289
  69. Aneja A , El Atat F , McFarlane SI , et al.   Hypertension and obesity . Recent Prog Horm Res . 2004;59:169–205
  70. Prasad A , Quyyumi AA . Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome . Circulation . 2004;110:1507–1512
  71. Ortlepp JR , Breuer J , Eitner F , et al.   Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia . Eur J Pharmacol . 2002;436:145–150
  72. Julius S , Kjeldsen SE , Weber M , et al.   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (the VALUE randomised trial) . Lancet . 2004;363:2022–2031
  73. Chertin B , Rolle U , Cascio S , et al.   Upregulation of angiotensin II receptors in reflux nephropathy . J Pediatr Surg . 2002;37:251–255
  74. Mento PF , Pica ME , Hilepo J , et al.   Increased expression of glomerular AT1 receptors in rats with myocardial infarction . Am J Physiol . 1998;275:H1247–H1253
  75. Modrall JG , Quinones MJ , Frankhouse JH , et al.   Upregulation of angiotensin II type 1 receptor gene expression in chronic renovascular hypertension . J Surg Res . 1995;59:135–140
  76. Nickenig G . Central role of the AT(1)-receptor in atherosclerosis . J Hum Hypertens . 2002;16(suppl):S26–S33
  77. Kim SE , Scheffel U , Szabo Z , et al.   In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist . J Nucl Med . 1996;37:307–311
  78. Mathews WB , Yoo SE , Lee SH , et al.   A novel radioligand for imaging the AT1 angiotensin receptor with PET . Nucl Med Biol . 2004;31:571–574
  79. Szabo Z , Speth RC , Brown PR , et al.   Use of positron emission tomography to study AT1 receptor regulation in vivo . J Am Soc Nephrol . 2001;12:1350–1358
  80. Gibson RE , Beauchamp HT , Fioravanti C , et al.   Receptor binding radiotracers for the angiotensin II receptor (radioiodinated [Sar1, Ile8]Angiotensin II) . Nucl Med Biol . 1994;21:593–600
  81. Owonikoko TK , Fabucci ME , Brown PR , et al.   In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET . J Nucl Med . 2003;45:94–100
  82. Goodfriend TL . Angiotensin receptors (History and mysteries) . Am J Hypertens . 2000;13:442–449
  83. de Gasparo M , Catt KJ , Inagami T , et al.   International union of pharmacology. XXIII: The angiotensin II receptors . Pharmacol Rev . 2000;52:415–472
  84. Hamill TG , Burns HD , Dannals RF , et al.   Development of [11C]L-159, 884 (a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging) . Appl Radiat Isotopes . 1996;47:211–218
  85. Hong KW , Kim CD , Lee SH , et al.   The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist . Fundam Clin Pharmacol . 1998;12:64–69
  86. Lee BH , Seo HW , Kwon KJ , et al.   In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist . J Cardiovasc Pharmacol . 1999;33:375–382
  87. Owonikoko TK , Fabucci ME , Brown PR , et al.   In vivo investigation of estrogen regulation of adrenal and renal angiotensin AT1 receptor expression by PET . J Nucl Med . 2003;45:94–100
  88. Guyton AC , Coleman TG , Manning RD , et al.   Some problems and solutions for modeling overall cardiovascular regulation . Mathematical Biosci . 1984;72:141–155
  89. Anderson WP , Ramsey DE , Takata M . Development of hypertension from unilateral renal artery stenosis in conscious dogs . Hypertension . 1990;16:441–451
  90. Tsuji Y , Goldfarb DA , Masaki Z , et al.   Patterns of renal function in hypertension due to unilateral renal artery occlusion . Clin Exp Hypertens A . 1992;14:1067–1081
  91. Admiraal PJ , Danser AH , Jong MS , et al.   Regional angiotensin II production in essential hypertension and renal artery stenosis . Hypertension . 1993;21:173–184
  92. Mai M , Hilgers KF , Wagner J , et al.   Expression of angiotensin-converting enzyme in renovascular hypertensive rat kidney . Hypertension . 1995;25:674X–678X
  93. Haefliger JA , Bergonzelli G , Waeber G , et al.   Renin and angiotensin II receptor gene expression in kidneys of renal hypertensive rats . Hypertension . 1995;26:733–737
  94. Wilkes BM , Pion I , Sollott S , et al.   Intrarenal renin-angiotensin system modulates glomerular angiotensin receptors in the rat . Am J Physiol . 1988;254:F345–F350
  95. Lu XY , Li XM , Li LY , et al.   Variation of intrarenal angiotensin II and angiotensin II receptors by acute renal ischemia in the aged rat . Renal Failure . 1996;18:19–29
  96. Regitz-Zagrosek V , Neuss M , Holzmeister J , et al.   Molecular biology of angiotensin receptors and their role in human cardiovascular disease . J Mol Med . 1996;74:233–251
  97. Ernst CB , Daugherty ME , Kotchen TA . Relatonship between collateral development and renin in experimental renal artery stenosis . Surgery . 1976;80:252–258
  98. Llorens-Cortes C , Greenberg B , Huang H , et al.   Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase-polymerase chain reaction analysis . Hypertension . 1994;24:538–548
  99. Unger T . The role of the renin-angiotensin system in the development of cardiovascular disease . Am J Cardiol . 2002;89:3A–9A
  100. Schieffer B , Schieffer E , Hilfiker-Kleiner D , et al.   Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques (potential implications for inflammation and plaque instability) . Circulation . 2000;101:1372–1378
  101. Pantuck AJ , Berger F , Zisman A , et al.   CL1-SR39 (A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography) . J Urol . 2002;168:1193–1198
  102. Textor SC . Ischemic nephropathy (Where are we now?) . J Am Soc Nephrol . 2004;15:1974–1982
  103. Gerhard A , Schwarz J , Myers R , et al.   Evolution of microglial activation in patients after ischemic stroke (a [11C](R)-PK11195 PET study) . Neuroimage . 2005;24:591–595
  104. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  105. Pantuck AJ , Zisman A , Belldegrun AS . The changing natural history of renal cell carcinoma . J Urol . 2001;166:1611–1623
  106. Chow WH , Devesa SS , Warren JL , et al.   Rising incidence of renal cell cancer in the United States . JAMA . 1999;281:1628–1631
  107. Sorger D , Patt M , Kumar P , et al.   [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO) (A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors) . Nucl Med Biol . 2003;30:317–326
  108. Rasey JS , Grunbaum Z , Magee S , et al.   Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells . Radiat Res . 1987;111:292–304
  109. Rasey JS , Koh WJ , Evans ML , et al.   Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole (A pretherapy study of 37 patients) . Int J Radiat Oncol Biol Phys . 1996;36:417–428
  110. Koh WJ , Rasey JS , Evans ML , et al.   Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole . Int J Radiat Oncol Biol Phys . 1992;22:199–212
  111. Fujibayashi Y , Taniuchi H , Yonekura Y , et al.   A Copper-62-ATSM (a new hypoxia imaging agent with high membrane permeability and low redox potential) . J Nucl Med . 1997;38:1155–1160
  112. Gronroos T , Eskola O , Lehtio K , et al.   Pharmacokinetics of [18F]FETNIM (A potential marker for PET) . J Nucl Med . 2001;42:1397–1404
  113. Evans SM , Kachur AV , Shiue CY , et al.   Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1 . J Nucl Med . 2000;41:327–336
  114. Rajendran JG , Wilson DC , Conrad EU , et al.   [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas (correlation of hypoxia, metabolism and VEGF expression) . Eur J Nucl Med Mol Imaging . 2003;30:695–704
  115. Dolbier WR , Li AR , Koch CJ , et al.   [18F]-EF5, a marker for PET detection of hypoxia (Synthesis of precursor and a new fluorination procedure) . Appl Radiat Isotopes . 2001;54:73–80
  116. Nishikibe M , Ohta H , Okada M , et al.   Pharmacological properties of J-104132 (L-753, 037), a potent orally active, mixed ETA/ATB endothelin receptor antagonist . J Pharmacol Exp Ther . 1999;289:1262–1270
  117. Aleksic S , Szabo Z , Scheffel U , et al.   In vivo labeling of endothelin receptors with [11C]L-735, 037 (Studies in mice and a dog) . J Nucl Med . 2001;42:1274–1280
  118. Chen X , Tohme M , Park R , et al.   Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide . Mol Imaging . 2004;3:96–104
  119. Haubner R , Weber WA , Beer AJ , et al.   Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD . PLoS Med . 2005;2:e70

 Supported by NIH grant number DK-50183.

PII: S0001-2998(05)00050-4

doi: 10.1053/j.semnuclmed.2005.08.003

Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 36-50 , January 2006

Article Tools

* Image Usage & Resolution